Skip to content
AdminJun 29, 2022< 1 min read

Assessing Re-identification Risk Using Synthetic Data

2022-06-29-Assessing-Re-identification-Risk-Using-Synthetic-Data

Lucy Mosquera, Director of Data Science, Replica Analytics

In this webinar, Replica’s Director of Data Science, Lucy Mosquera, presents a novel approach to employ synthetic data for a more accurate assessment of re-identification risks in datasets, to better manage privacy risks and enable greater data sharing in healthcare and other sectors.

 

 

Following the acquisition of Replica Analytics by Aetion, the generative AI technology previously known as Replica Synthesis is now Aetion® Generate and continues to create privacy-enhancing synthetic data.
Learn More

RELATED ARTICLES

AdminOct 31, 20243 min read

Applying AI to RWE and Drug Development

With applications abound, AI is poised to change how RWD/RWE teams operate and how quickly they can accelerate drug ...
Start Reading
AdminOct 31, 20243 min read

What’s Next for Healthcare in 2025: Emerging Threats, GLP-1 Inhibitors, AI, and the Power of RWE

As 2024 comes to a close and 2025 gets going, major changes in healthcare and drug development loom. Emerging infectious ...
Start Reading
AdminOct 30, 20241 min read

Evaluating Real-World Use of Botulinum Toxins for Cervical Dystonia, Blepharospasm, and Hemifacial Spasm

Movement disorders like cervical dystonia, blepharospasm, and hemifacial spasm can greatly diminish the quality of life for ...
Start Reading